Evidence map›Paper›PMID 36641816›Full record

ArticleThe International journal on drug policy2023

How the rural risk environment underpins hepatitis C risk: Qualitative findings from rural southern Illinois, United States.

Suzan M Walters, David Frank, Marisa Felsher, Jessica Jaiswal, Scott Fletcher, Alex S Bennett, Samuel R Friedman, Lawrence J Ouellet, Danielle C Ompad, Wiley Jenkins and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The International journal on drug policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Untangling the Web of Hepatitis C Risk in Rural Communities.Journal of general internal medicine · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. "I'm tired of seeing my friends die": Barriers and facilitators to participating in clinical trials among rural people who use drugs in the United States.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. A National Portrait of Public Attitudes toward Opioid Use in the US: A Latent Class Analysis.International journal of environmental research and public health · 2023
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Suzan M WaltersDepartment of Epidemiology, New York University School of Global Public Health, New York, NY, United States; Center for Drug Use and HIV/HCV Research, New York, NY, United States. Electronic address: smk556@nyu.edu.
David FrankDepartment of Epidemiology, New York University School of Global Public Health, New York, NY, United States; Center for Drug Use and HIV/HCV Research, New York, NY, United States.
Marisa FelsherCollege of Population Health, Thomas Jefferson University, United States.
Jessica JaiswalDepartment of Health Science, University of Alabama, Tuscaloosa, AL, United States.
Scott FletcherDepartment of Epidemiology, New York University School of Global Public Health, New York, NY, United States; Center for Drug Use and HIV/HCV Research, New York, NY, United States; College of Population Health, Thomas Jefferson University, United States; Department of Health Science, University of Alabama, Tuscaloosa, AL, United States; Department of Social and Behavioral Sciences, New York University School of Global Public Health, New York, NY, United States; Department of Population Health, New York University Grossman School of Medicine, United States; Division of Epidemiology & Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, IL, United States; Department of Population Science and Policy, SIU School of Medicine, Springfield, IL, United States; Department of Medicine, University of Chicago, Chicago, IL, United States; The Community Action Place, Murphysboro, IL, United States.
Alex S BennettCenter for Drug Use and HIV/HCV Research, New York, NY, United States; Department of Social and Behavioral Sciences, New York University School of Global Public Health, New York, NY, United States.
Samuel R FriedmanCenter for Drug Use and HIV/HCV Research, New York, NY, United States; Department of Population Health, New York University Grossman School of Medicine, United States.
Lawrence J OuelletDivision of Epidemiology & Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, IL, United States.
Danielle C OmpadDepartment of Epidemiology, New York University School of Global Public Health, New York, NY, United States; Center for Drug Use and HIV/HCV Research, New York, NY, United States.
Wiley JenkinsDepartment of Population Science and Policy, SIU School of Medicine, Springfield, IL, United States.
Mai T PhoDepartment of Medicine, University of Chicago, Chicago, IL, United States.
New York University · USThomas Jefferson University · USSouthern Illinois University School of Medicine · USUniversity of Alabama · USUniversity of Chicago · USUniversity of Illinois Chicago · US

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI LINDA M COLLINS · 1998 to 2026
$38.9M
BEHAVIORAL SCI TRAINING IN DRUG ABUSE RESEARCHT32DA007233 · NIDA · PUBLIC HEALTH SOLUTIONS · PI GOLDSAMT, LLOYD A · 1985 to 2023
$20.2M
Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI ELBERT S. HUANG · 2011 to 2026
$10.0M
Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
The Lifespan/Brown Criminal Justice Research Program on Substance Use and HIVR25DA037190 · NIDA · MIRIAM HOSPITAL · PI CURT G BECKWITH · 2014 to 2026
$3.5M
Intersectional Stigma Experiences, Pre-exposure Prophylaxis (PrEP), and Other Service Use Among People Who Inject DrugsK01DA053159 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WALTERS, SUZAN M · 2021 to 2025
$927k
NCATS NIH HHS UL1 TR001445NIDA NIH HHS K01 DA053159NIDA NIH HHS P30 DA011041NIDA NIH HHS R25 DA037190NIDA NIH HHS T32 DA007233NIDA NIH HHS UH3 DA044829NIDDK NIH HHS P30 DK092949
6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) infection has increased among persons who inject drugs (PWID) in the United States with disproportionate burden in rural areas. We use the Risk Environment framework to explore potential economic, physical, social, and political determinants of hepatitis C in rural southern Illinois.

methodsNineteen in-depth semi-structured interviews were conducted with PWID from August 2019 through February 2020 (i.e., pre-COVID-19 pandemic) and four with key informants who professionally worked with PWID. Interviews were recorded, professionally transcribed, and coded using qualitative software. We followed a grounded theory approach for coding and analyses.

resultsWe identify economic, physical, policy, and social factors that may influence HCV transmission risk and serve as barriers to HCV care. Economic instability and lack of economic opportunities, a lack of physically available HCV prevention and treatment services, structural stigma such as policies that criminalize drug use, and social stigma emerged in interviews as potential risks for transmission and barriers to care.

conclusionThe rural risk environment framework acknowledges the importance of community and structural factors that influence HCV infection and other disease transmission and care. We find that larger structural factors produce vulnerabilities and reduce access to resources, which negatively impact hepatitis C disease outcomes.

Indexed as

COVID-19Drug UsersHepatitis CSubstance Abuse, IntravenousHepacivirusHumansIllinoisPandemicsUnited StatesHepatitis CInjection drug useRural risk environment

Identifiers

PMID36641816
PMCPMC9974910
OpenAlexW4316021739

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.